Cincinnati, OH, United States of America

Kevin Gene Peters

This inventor holds 35 USPTO granted patents and 37 published patent applications, plus 7 CIPO patents and 11 EPO patents, primarily in Ocular Therapeutics. Top assignees: Aerpio Therapeutics, Inc., Eyepoint Pharmaceuticals, Inc., Aerpio Pharmaceuticals, Inc.. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kevin Gene Peters. Retrieved from https://idiyas.com/inventor/kevin-gene-peters

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 35 (Patent Applications = 37)

% Patents Active = 100.0

CIPO Patents = 7 (Patent Applications = 3)

EPO Patents = 11 (Patent Applications = 19)

Average Co-Inventor Count = 1.6

ph-index = 13

Forward Citations = 427(Granted Patents)

Company Filing History:

14 out of 35

Aerpio Therapeutics, Inc.

patents

13 out of 23

Eyepoint Pharmaceuticals, Inc.

patents

7 out of 8

Aerpio Pharmaceuticals, Inc.

patents

4. 1 out of 1

Aeripo Therapeutics Inc.

patent

Years Active: 2013-2026

Loading Chart...

Areas of Expertise:

Tie-2 Activators

Ocular Conditions

Monoclonal Antibodies

VE-PTP

HPTP-Beta

Vascular Leak Syndrome

Cancer Treatment

Intraocular Pressure

Immunotherapy

Formulations

Compositions

Antibodies

35 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12544362 - Methods of treating acute respiratory distress syndrome with activators of Tie-2 (2026-02-10),

2. 12398204 - Method of treating an ocular condition by administering multispecific antibodies that activates TIE2 and binds a receptor tyrosine kinase agonist (2025-08-26),

3. 12171751 - Methods of treating intraocular pressure with activators of Tie-2 (2024-12-24),

4. 12152023 - Compositions, formulations and methods for treating ocular diseases (2024-11-26),

5. 12145986 - Method of treating an ocular condition by administering a humanized monoclonal antibodies that target VE-PTP (HPTP-Beta) (2024-11-19),

6. 12064420 - Tie-2 activators targeting the Schlemm's canal (2024-08-20),

7. 12043664 - Methods for treating vascular leak syndrome and cancer (2024-07-23),

8. 11873334 - Method of treating ocular conditions by administering an antibody that activates Tie2 and binds VEGF (2024-01-16),

9. 11814425 - Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof (2023-11-14),

10. 11666558 - Methods of treating intraocular pressure with activators of Tie-2 (2023-06-06),

11. 11413242 - Formulations of Tie-2 activators and methods of use thereof (2022-08-16),

12. 11253502 - Tie-2 activators targeting the Schlemm's canal (2022-02-22),

13. 11180551 - Humanized monoclonal antibodies that target VE-PTP (HPTP-beta) (2021-11-23),

14. 11136389 - Humanized monoclonal antibodies that target VE-PTP (HPTP-β) (2021-10-05),

15. 10952992 - Methods of treating intraocular pressure with activators of Tie-2 (2021-03-23),

Title: Kevin Gene Peters - Innovative Inventor from Cincinnati

Introduction: Kevin Gene Peters is a talented inventor based in Cincinnati, Ohio, known for his groundbreaking contributions to various industries.

Latest Patents: Kevin Gene Peters holds several patents in the fields of technology, healthcare, and consumer products, showcasing his diverse range of innovative ideas.

Career Highlights: With a career spanning over two decades, Kevin Gene Peters has established himself as a visionary inventor with a keen eye for identifying gaps in the market and developing unique solutions to address them.

Collaborations: Throughout his career, Kevin Gene Peters has collaborated with leading companies, research institutions, and universities to bring his inventions to life, demonstrating his ability to work effectively in multidisciplinary teams.

Conclusion: Kevin Gene Peters continues to push the boundaries of innovation, and his passion for creating impactful solutions is evident in his impressive body of work.

Profile summary based on public USPTO records.